3-(2-羟基苯基)苯甲酸 | 893736-72-6

• 物质功能分类: 有机原料 - 羧酸类化合物及衍生物
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 3-(2-羟基苯基)苯甲酸
• 中文别名: 2-羟基联苯-3-羧酸
• 英文名称: 2'-hydroxybiphenyl-3-carboxylic acid
• 英文别名: 2'-Hydroxy-[1,1'-biphenyl]-3-carboxylic acid；3-(2-hydroxyphenyl)benzoic acid
• CAS: 893736-72-6
• 化学式: C₁₃H₁₀O₃
• 分子量: 214.221
• InChiKey: OCZVWZVTEQXRPI-UHFFFAOYSA-N

物化性质

• 沸点：
  427.3±28.0 °C(Predicted)
• 密度：
  1.292±0.06 g/cm3(Predicted)
• 溶解度：
  可溶于DMSO（少许）、甲醇（少许）

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  57.5
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 海关编码：
  2922299090

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 2’-Hydroxybiphenyl-3-carboxylic acid
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 2’-Hydroxybiphenyl-3-carboxylic acid
CAS number: 893736-72-6

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C13H10O3
Molecular weight: 214.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  3-(2-羟基苯基)苯甲酸 在 氢溴酸 、 溶剂黄146 、 硝酸 作用下， 生成 2-羟基-3-硝基-联苯-3-羧酸
  参考文献：
  名称：

  WO2006/47344

  摘要：

  公开号：
• 作为产物：
  描述：

  3'-氨基-2'-羟基-[1,1'-联苯]-3-甲酸 在 盐酸 、 sodium nitrite 、 phosphonyl radical 作用下， 以 甲醇 、 水 为溶剂， 反应 1.0h， 以80%的产率得到3-(2-羟基苯基)苯甲酸
  参考文献：
  名称：

  艾曲波帕乙醇胺潜在杂质的合成和表征

  摘要：

  这项工作报告了最近开发的以 2-溴-6-硝基苯酚为原料生产艾曲波帕乙醇胺的工业可行工艺的可行性，并报告了与艾曲波帕乙醇胺相关的四种潜在杂质的鉴定，即艾曲波帕乙醇胺酯 (1)、2-氨基苯酚类似物艾曲波帕 (2)、3,3'-(2-氨基-3-氧代-3H-吩恶嗪-4,6-二基二苯甲酸 (3)、2'-羟基[1,1-联苯]-3-羧酸(4).这些杂质是在生产过程中决定艾曲波帕乙醇胺原料药质量的关键成分，这些杂质对艾曲波帕乙醇胺的质量有影响，控制这些杂质可以使艾曲波帕乙醇胺的活性药物成分获得优异的收率

  DOI：

  10.14233/ajchem.2021.22951

文献信息

• CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS
  申请人：POLYPHOR AG

  公开号：US20150051183A1

  公开（公告）日：2015-02-19

  The conformationally restricted, spatially defined macrocyclic ring system of formula (I) is constituted by three distinct molecular parts: Template A, conformation Modulator B and Bridge C. Macrocycles described by this ring system I are readily manufactured by parallel synthesis or combinatorial chemistry in solution or on solid phase. They are designed to interact with a variety of specific biological target classes, examples being agonistic or antagonistic activity on G-protein coupled receptors (GPCRs), inhibitory activity on enzymes or antimicrobial activity. In particular, these macrocycles show inhibitory activity on endothelin converting enzyme of subtype 1 (ECE-1) and/or the cysteine protease cathepsin S (CatS), and/or act as antagonists of the oxytocin (OT) receptor, thyrotropin-releasing hormone (TRH) receptor and/or leukotriene B4 (LTB4) receptor, and/or as agonists of the bombesin 3 (BB3) receptor, and/or show antimicrobial activity against at least one bacterial strain. Thus they are showing great potential as medicaments for a variety of diseases.

  公式（I）的构象受限、空间定义的大环环系统由三个不同的分子部分组成：模板A、构象调节剂B和桥C。由这种环系统I描述的大环可通过并行合成或溶液中或固相上的组合化学轻松制造。它们被设计用于与各种特定生物靶标类相互作用，例如在G蛋白偶联受体（GPCR）上的激动或拮抗活性，酶的抑制活性或抗菌活性。特别是，这些大环显示对亚型1的内皮素转化酶（ECE-1）和/或半胱氨酸蛋白酶卡特普辛S（CatS）的抑制活性，和/或作为催产素（OT）受体、促甲状腺释放激素（TRH）受体和/或白三烯B4（LTB4）受体的拮抗剂，和/或作为瘤胃素3（BB3）受体的激动剂，和/或对至少一种细菌菌株显示抗菌活性。因此，它们显示出作为各种疾病药物的巨大潜力。
• A focused fragment library targeting the antibiotic resistance enzyme - Oxacillinase-48: Synthesis, structural evaluation and inhibitor design
  作者：Sundus Akhter、Bjarte Aarmo Lund、Aya Ismael、Manuel Langer、Johan Isaksson、Tony Christopeit、Hanna-Kirsti S. Leiros、Annette Bayer

  DOI：10.1016/j.ejmech.2017.12.085

  日期：2018.2

  β-lactamase inhibitors and today several β-lactamase inhibitors e.g. avibactam, are approved in the clinic. Our focus is the oxacillinase-48 (OXA-48), an enzyme reported to spread rapidly across the world and commonly identified in Escherichia coli and Klebsiella pneumoniae. To guide inhibitor design, we used diversely substituted 3-aryl and 3-heteroaryl benzoic acids to probe the active site of OXA-48

  当在医学界中治疗细菌感染时，β-内酰胺抗生素至关重要。然而，目前它们的效用受到β-内酰胺抗性的出现和扩散的威胁。对β-内酰胺抗生素最普遍的耐药机制是β-内酰胺酶的表达。克服由β-内酰胺酶引起的抗性的一种方法是开发β-内酰胺酶抑制剂，如今临床上已经批准了几种β-内酰胺酶抑制剂，例如阿维巴坦。我们的研究重点是oxacillinase-48（OXA-48），据报道该酶在世界范围内迅速传播，通常在大肠杆菌和肺炎克雷伯菌中得到鉴定。为了指导抑制剂的设计，我们使用了不同取代的3-芳基和3-杂芳基苯甲酸来探测OXA-48的活性位点，以进行有用的酶-抑制剂相互作用。在本研究中，合成了包含49个3-取代的苯甲酸衍生物的聚焦片段文库，并对其进行了生化表征。基于从33片段的酶复合物晶体学数据，片段可以被归类为R 1或R 2个可以通过总体结合构象相对于粘合剂到R的结合1和R 2亚胺培南的侧基。此外，发现了对未来抑
• [EN] PROCESSES FOR THE PREPARATION OF AN INTERMEDIATE IN THE SYNTHESIS OF ELTROMBOPAG<br/>[FR] PROCÉDÉS DE PRÉPARATION D'UN INTERMÉDIAIRE DANS LA SYNTHÈSE DE L'ELTROMBOPAG
  申请人：ASSIA CHEM IND LTD

  公开号：WO2013049605A1

  公开（公告）日：2013-04-04

  3'-Amino-2'-hydroxybiphenyl-3-carboxylic acid (BPCA) and related compounds have been prepared using compounds such as: wherein R1 is -H, -Cl or -F; R2 is -Br or -I; and R3 is -H or -N02. BPCA is useful, for example, in the preparation of Eltrombopag.

  3'-氨基-2'-羟基联苯-3-羧酸（BPCA）及相关化合物已经利用化合物制备，其中R1为-H、-Cl或-F；R2为-Br或-I；R3为-H或-N02。例如，BPCA在埃替莫帕格的制备中是有用的。
• [EN] CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS<br/>[FR] COMPOSÉS MACROCYCLIQUES ENTIÈREMENT SYNTHÉTIQUES ET À CONFORMATION CONTRAINTE
  申请人：POLYPHOR AG

  公开号：WO2013139697A1

  公开（公告）日：2013-09-26

  The conformationally restricted, spatially defined macrocyclic ring system of formula (I) is constituted by three distinct molecular parts: Template A, conformation Modulator B and Bridge C. Macrocycles described by this ring system I are readily manufactured by parallel synthesis or combinatorial chemistry in solution or on solid phase. They are designed to interact with a variety of specific biological target classes, examples being agonistic or antagonistic activity on G-protein coupled receptors (GPCRs), inhibitory activity on enzymes or antimicrobial activity. In particular, these macrocycles show inhibitory activity on endothelin converting enzyme of subtype 1 (ECE-1 ) and/or the cysteine protease cathepsin S (CatS), and/or act as antagonists of the oxytocin (OT) receptor, thyrotropin-releasing hormone (TRH) receptor and/or leukotriene B4 (LTB4) receptor, and/or as agonists of the bombesin 3 (BB3) receptor, and/or show antimicrobial activity against at least one bacterial strain. Thus they are showing great potential as medicaments for a variety of diseases.

  公式（I）的构象受限、空间定义明确的大环环形系统由三个不同的分子部分构成：模板A、构象调制剂B和桥梁C。由该环系统I描述的大环可通过溶液中的并行合成或组合化学，或者在固相上制造。它们被设计用来与各种特定生物靶标类相互作用，例如在G蛋白偶联受体（GPCR）上的激动或拮抗活性，对酶的抑制活性或抗菌活性。特别是，这些大环显示对第1亚型内皮素转化酶（ECE-1）和/或半胱氨酸蛋白酶S（CatS）的抑制活性，和/或作为催产素（OT）受体、促甲状腺释放激素（TRH）受体和/或白三烯B4（LTB4）受体的拮抗剂，和/或作为瘤胃肽3（BB3）受体的激动剂，和/或对至少一种细菌菌株显示抗菌活性。因此，它们显示出作为各种疾病药物的巨大潜力。
• Structure-based discovery of glycomimetic FmlH ligands as inhibitors of bacterial adhesion during urinary tract infection
  作者：Vasilios Kalas、Michael E. Hibbing、Amarendar Reddy Maddirala、Ryan Chugani、Jerome S. Pinkner、Laurel K. Mydock-McGrane、Matt S. Conover、James W. Janetka、Scott J. Hultgren

  DOI：10.1073/pnas.1720140115

  日期：2018.3.20

  of ∼90 nM, representing a major advancement in potency relative to the characteristically weak nature of most carbohydrate–lectin interactions. 29β-NAc binds tightly to FmlH by engaging the residues Y46 through edge-to-face π-stacking with its A-phenyl ring, R142 in a salt-bridge interaction with its carboxylate group, and K132 through water-mediated hydrogen bonding with its N-acetyl group. Administration

  由于在全球范围内传播多药抗生素耐药性，细菌感染的治疗正成为一项严重的临床挑战，因此有必要寻找替代疗法来消除这些感染的致病机制。泌尿道致病性大肠杆菌（UPEC）使用多种分子伴侣-胶合剂通路菌毛，其中的黏附素具有不同的受体特异性，可以在各种宿主组织和生境中定殖。例如，UPEC F9菌毛特异性结合在肾脏和发炎的膀胱上的半乳糖或N-乙酰半乳糖胺表位。使用X射线结构指导方法，虚拟筛选和多重ELISA阵列，我们合理设计了芳基半乳糖苷和N抑制F9菌毛粘附素FmlH的-乙酰半乳糖氨基糖苷。铅化合物29β-NAc是具有K i的联苯基N-乙酰基-β-半乳糖氨基糖苷大约90 nM，相对于大多数碳水化合物-凝集素相互作用的特征较弱的特性，其效能有了很大的提高。29β-NAc通过与A46环通过面对面π堆叠与残基Y46，与羧酸酯基团进行盐桥相互作用的R142和与水通过氢键结合的K132与残基Y46紧密结合，从而与FmlH紧密结合。